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Abstract
Background: Bone Marrow (BM) progenitor cells can target the site of myocardial injury, contributing
to tissue repair by neovascolarization and/or by a possible direct paracrine effect on the inflammatory
cascade. Angiotensin Converting Enzyme inhibitors (ACE-I) are effective in reducing mortality and
preventing left ventricular (LV) function deterioration after myocardial infarction.
Methods: We investigated the short term effects of BM mononuclear cells (BMMNCs) therapy on the
pro-inflammatory cytokines (pro-CKs) and on LV remodelling and compared these effects over a standard
ACE-I therapy in a rat model of myocardial cryodamage.
Forty two adult inbread Fisher-F344 rats were randomized into three groups: untreated (UT; n = 12),
pharmacological therapy (ACE-I; n = 14, receiving quinapril), and cellular therapy (BMMNCs; n = 16,
receiving BMMNCs infusion). Rats underwent to a standard echocardiogram in the acute setting and 14
days after the damage, before the sacrifice. Pro-CKs analysis (interleukin (IL)1β, IL-6, tumor necrosis factor
(TNF)α was performed (multiplex proteome arrays) on blood samples obtained by direct aorta puncture
before the sacrifice; a control group of 6 rats was considered as reference.
Results: Concerning the extension of the infarcted area as well as the LV dimensions, no differences were
observed among the animal groups; treated rats had lower left atrial diameters and higher indexes of LV
function. Pro-Cks were increased in infarcted-UT rats if compared with controls, and significantly reduced
by BMMNCs and ACE-I ; TNFα inversely correlated with LV fractional shortening.
Conclusion:  After myocardial infarction, both BMMNCs and ACE-I reduce the pattern of pro-Ck
response, probably contributing to prevent the deterioration of LV function observed in UT rats.
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Background
After myocardial infarction the host response includes
inflammatory response and cytokine production, that
modulate tissue repair and response and are determinant
for the patient outcome [1].
Experimental animal studies have provided evidence that
bone marrow (BM) progenitor cells are capable to selec-
tively target the site of myocardial injury [2] and contrib-
ute to tissue repair [3]. More recently the interest has
focused on the hypothesis that BM progenitors could
ameliorate left ventricular (LV) remodeling following
myocardial infarction by continuing to differentiate along
the hematopoietic lineage [4]. But currently no evidences
have been provided demonstrating that in animals trans-
planted with different stem or progenitor cell populations
the damaged area has been partially or completely regen-
erated by new cardiomyocytes. Unfortunately the homing
have been shown to be transient [5] and only few trans-
planted cells have been found in the site of the myocardial
injury [6] even if cardiac functions have been observed to
ameliorate. Therefore, other possible explanations have
been proposed in order to clarify the mechanisms under-
lying the positive results observed in animals models and
humans. In this context, a possible mechanism of the BM
cell therapy benefit could derive either by new vessels for-
mation [7,8] at the infarct site and/or by a direct paracrine
effect on the inflammatory cascade [9].
On the other hand, several clinical studies based on cell
therapy with stem and progenitors cells are producing
interesting but still debated results [10-12].
Angiotensin Converting Enzyme inhibitors (ACE-I) are
considered a first line therapy following myocardial inf-
arction in humans because of their demonstrated efficacy
in reducing mortality and preventing deterioration of LV
function [13], partially due to a reduction in cardiac
cytokine expression in the subacute and chronic period
after the injury [14,15].
In this general context no studies are available comparing
the efficacy of BM progenitors cells with conventional
ACE-I therapy after myocardial infarction.
In the hypothesis that the efficacy of BM mononuclear
cells (BMMNCs) after myocardial infarction is mediated
by a paracrine mechanism, in this study we investigated
the short term effects of BMMNC therapy on the pro-
inflammatory cytokine (pro-Ck) signaling pathways and
on LV remodelling markers and compared these effects
over a standard ACE-I pharmacological therapy in a rat
model of myocardial cryodamage. By using an animal
model that allows to mimic the autologous infusion of
BM progenitors avoiding immunosuppression and an
experimental myocardial injury procedure that facilitates
the association of transplanted cells with the infarcted ver-
sus the non infarcted areas [16], we have shown, for the
first time, that peripherally injected BMMNCs signifi-
cantly reduce the pro-Ck response.
Methods
Animal model and experimental myocardial cryoinjury
A total number of 42 male adult inbred rats (Fisher-F344;
Charles River Laboratories, Italy) weighting 200–250 g.
were studied. Animals were housed and handled in
accordance with the "Guide for the Care and Use of Labo-
ratory Animals" [17]. To ensure the permanent identifica-
tion, at the arrival each rat was implanted with a
microchip device (MUSICC, AVID Microchip, Barcelona,
Spain). Experimental myocardial cryoinjury was pro-
duced by freeze-thaw technique, previously described in
detail [16], that allows producing a predictable cardiac
lesion. The animals were therefore randomized into three
groups: untreated group receiving no treatment (UT; n =
12), pharmacological therapy group treated with quin-
april (ACE-I; n = 14), and cellular therapy group treated
with BMMNCs infusion (BMMNCs; n = 16) (Figure 1).
Isolation, characterization, labeling and administration of 
BMMNCs
Thirty two rats were used as donors of BMMNCs; isolation
of cells from the femoral and tibial bones of donor rats
and labeling and administration in recipient rats (n = 16)
were performed according to a previously described
method [2]. The number of BMMNCs expressing the
CD34 surface marker and the viability of pooled cells were
assessed by flow-cytometry analysis of 100,000 events per
sample (FACScan, Becton Dickinson, Franklin Lakes, NJ).
Before administration, cells were labeled with a red fluo-
rescent cell linker (PKH26 dye, Sigma, St. Louis, MO).
Seven days after injury, the recipient rats were prepared for
the infusion of a single dose of BMMNCs. Rats were anes-
thetized (ketamine, 2 g/Kg body weight i.p.) and the fem-
oral vein was surgically isolated and exposed. The
BMMNCs suspension (500 μL) containing 20 ± 2.1 × 106
cells, with a mean of 1.03 ± 0.2% CD34+, was infused
using a sterile tuberculin syringe with a 23G needle. The
wound was then closed with 5-0 vicryl sutures.
ACE-I treatment
The ACE-I quinapril, with a known high heart tissue ACE
affinity [18], was administered orally in drinking water
and adjusted to reach the dose of 1 mg/kg/die. The treat-
ment was started the day after myocardial cryoinjury and
followed for 14 days, with an overall administation of
1.75 mg of quinapril in each treated rat.Journal of Translational Medicine 2008, 6:30 http://www.translational-medicine.com/content/6/1/30
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Echocardiographic examination
In vivo heart dimensions, function and infarct size were
evaluated by standard echocardiography by using an
echocardiographic system (GE Vivid 7, Wisconsin, USA)
equipped with a 13 MHz linear array probe (focus depth
set at 1.0 cm). Rats were examined under diethyl ether
anesthesia, in the left lateral decubitous position, before
the cryodamage, in the acute setting (within 24 hours after
the injury) and before the sacrifice, 14 days after the
injury. Infarct size was assessed at the end of the study by
planimetry on 2D, short-axis acquired in real time images
of the LV according to a previous described procedure [2].
Pathological examination
Fourteen days after the myocardial damage rats were sac-
rificed with an overdose of sodium pentobarbital. The
heart was exposed through a sternotomy. The heart was
then arrested in diastole with an injection of potassium
chloride (10 mEq) and the site of myocardial injury was
identified by gross examination. In order to obtain ade-
quate material for the different investigations, the heart
was sampled, the infarcted region was transversely cut
into two sections of about 5 mm in thickness and frozen
in cryostat embedding medium (Bio Optica, Milan, Italy).
From each frozen block 5 μm thick cryostatic sections
were obtained and used to evaluate the morphology of the
infarcted region and to perform the immunoreactions.
Immunostaining was performed by using the following
primary antibodies at the following dilutions: Sarcomeric
Actin, 1:200 from Dako (Dako A/S, Glostrup, Denmark);
CD34, 1:100 (clone ICO115) purchased from Santa Cruz
Biotechnology Inc. (Becton Dickinson, Santa Cruz, CA,
USA).
Design of the experiment Figure 1
Design of the experiment.Journal of Translational Medicine 2008, 6:30 http://www.translational-medicine.com/content/6/1/30
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Serum cytokine assay
Cytokine profile analysis was performed by chemilumi-
nescent enzyme immunometric assay (SearchLight Pro-
teome Array, USA) on 50 ml serum samples (diluted 1:5)
obtained by direct puncture of the aorta 14 days after the
myocardial damage, before the sacrifice. The array layout
included the following 9 cytokines: interleukin (IL)-1α,
IL-1β, IL-2, IL-4, IL-6, IL-10, interferon (IFN)γ, tumor
necrosis factor (TNF)α, granulocyte-macrophage colony-
stimulating factor (GMCSF); of them, the pro-CKs
included in the study were IL-1β. IL-6, TNFα. The lower
detection limit for each cytokine was set according to the
manufacturer. Normal cytokine values were obatined
from an age and sex matched control group (n = 6).
Morphometrical analyses
The homing of the injected population to the tissue target
and their phenotype was confirmed by immunofluores-
cence and immunohistochemistry using a previously
described approach [8]. Briefly, immunofluorescence was
revealed with a multi-photon confocal microscope (Bio-
Rad Radiance 2100, Carl Zeiss, Germany) using HeNe
laser (543 nm). In each section at least 6 fields (20×) cor-
responding to the infarcted/non-infarcted areas were
selected, acquired and stored on a personal computer
(Power Mac G4, 867 Mhz, 640 MB RAM, Apple, Cuper-
tino, USA) in JPEG format (5:1) by using a CCD camera
(COHU 2200, Cohu Inc., San Diego, CA, USA) coupled to
an analog-to-digital acquisition board (Dazzle DV-Bridge,
SCM Microsystems, Munich, Germany) operating at 32
bits/pixel on a 764 × 560 pixel matrix. Finally, stored
images were analyzed to confirm the homing of PKH26+/
CD34+ cells by using a computer integrated image-
processing software according to a previously described
procedure [8].
Immunohistochemistry
Sections from formalin fixed, paraffin embedded rat IMA
myocardial samples were incubated with Goat anti Rat
TNFα polyclonal antibody diluted 1:200 (Santa Cruz Bio-
technology Inc. Becton Dickinson, Santa Cruz, CA, USA).
Previous antigen retrieval was obtained by 30 min in
90°C citrate buffer. Positive (lymph node) and negative
(healthy rat myocardium) controls were added.
Statistical analysis
Data were analyzed using a computer statistical software
(SPSS – Rel 11; SPSS Inc., Chicago, Illinois, USA). Inf-
arcted areas are reported as mean ± standard deviation.
The effects of the two treatments on LV function and pro-
Cks were tested with ANOVA with Fisher's post hoc test.
The serum levels of each cytokine were correlated with LV
function parameters by linear regression analysis. All sta-
tistics were considered significant with p value less than
0.05.
Results
At the end of the study, the mean area of infarction in the
studied animals measured in vivo by echocardiography
was 21.7 ± 3.2% of the transverse LV free wall. Gross
examination of the excised hearts confirmed the presence
of a regular non-transmural scar of the entire LV free wall.
Histology confirmed the presence of a hemorrhagic inf-
arct, without transition zones from non-infarcted to inf-
arcted areas. No significant differences were found when
comparing the infarcted area in BMMNCs versus ACE-I
treated rats (23.4 ± 3.2 vs 20.4 ± 2.7%, respectively; p =
0.08). Confocal microscopy confirmed that in BMMNCs
treated rats PKH26+/CD34+ elements targeted the inf-
arcted areas (mean 13.9 ± 4.6 cells per field).
Fourteen days after the experimental myocardial damage
a significant increase in the serum levels of pro-CKs was
found in infarcted-UT rats if compared with non-infarcted
control rats (Table 1). Treatment with ACE-I and
BMMNCs resulted in significant lower serum levels of
pro-CKs in comparison with infarcted-UT rats (Table 2).
The extent of these differences in the pro-CKs were similar
in both treatment groups for IL-1β, while for IL-6 and
TNFα it was greater in BMMNCs treatment, even if the dif-
ference between the two treatment was not statistical sig-
nificant. When examining the other cytokines included in
the array, an effect was observed only on IL-4 that was sig-
nificantly reduced in both treatment groups if compared
with untreated rats, with no statistically significant differ-
ences between BMMNCs and ACE-I (IL-4: Controls 1.3 ±
0.8 pg/ml; UT 31.1 ± 9.1 pg/ml; ACE-I 9.6 ± 23.6 pg/ml;
BMMNCs 1.5 ± 2.6 pg/ml; UT vs Controls, p = 0.003; UT
vs ACE-I, p = 0.005; UT vs BMMNCs p = 0.0001; ACE-I vs
BMMNCs, p = ns). The patterns of pro-Cks responses are
shown in figure 2.
LV dimensions in both treated groups were not substan-
tially different if compared with untreated, while left atrial
diameters were lower in treated rats. Diastolic and systolic
indexes of LV function were still within the normal range
in all groups, even if fractional shortening (FS) was statis-
tically significant higher in both treated rats; finally, ejec-
tion fraction (EF) was higher in ACE-I treated rats (Table
3). When comparing serum pro-Ck levels in infarcted ani-
mals with LV function, an inverse significant correlation
was found between TNFα and FS (r = 0.84; p = 0.008).
The effects of treatments on TNFα circulating levels were
also confirmed locally by the immunohistochemistry
(Figure 3).
Discussion
Following the hypothesis that the mechanisms of poten-
tial effects of BM progenitors after myocardial infarction
can be due also to a direct paracrine effect on the inflam-Journal of Translational Medicine 2008, 6:30 http://www.translational-medicine.com/content/6/1/30
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matory cascade, in this study for the first time we have
studied the secretion of pro-Cks in the subacute phase of
the damage (14 days from the injury) after peripherally
injected BMMNCs and we compared these results with the
ones obtained with the conventional pharmacological
treatments.
It is well known that cytokines such as TNF-α or IL-1β and
IL-6 are not constitutively expressed in the normal heart;
they are secreted after myocardial ischemic injury, with
very important acute and chronic effects on myocardium,
including myocyte apoptosis and hypertrophy, defects on
contractility and inflammatory signal transduction, acti-
vation of matrix metalloproteinases and collagen forma-
tion, integrin regulation, angiogenesis and progenitor
cells mobilization.
In this context, we have shown that peripherally injected
BMMNCs reduce the pro-Cks response in the subacute
phase of the damage (14 days from the injury), when it is
documented to be significantly increased [19]. And in par-
ticular, the administration of BMMNCs decreased the
serum levels of IL-1β, IL-6 and TNFα that are from four-
fold to ninefold lower that in untreated rats.
Moreover, in these experiments, our model of cryoinjury
has been shown to be reliable in terms of inflammatory
response since the levels of these inflammatory cytokines
are very low in controls with a prompt increase after the
injury (7 days) of about 25 to 540 fold.
The role played by ACE-I in the modulation of inflamma-
tory response is still debated. While previous in vivo stud-
ies using ACE-I with low [20] or mild [15] tissue potency,
according to Dzau et al. [21], didn't find a significant anti-
cytokine effect, in agreement with other authors [14] we
observed a decrease in cytokine serum levels also in the
ACE-I treated group, indicating that quinapril is able to
reduce the pro-Cks release when introduced early (same
day of the injury). This finding supports the evidence that
some of the effects observed with quinapril are related to
its high affinity for tissue ACE.
Top panels Figure 2
Top panels. Representative original chemiluminescent images obtained from the studied rats. The loading scheme of the 
cytokines is shown on the first top left image. Bottom panels. Surface plots obtained from the corresponding chemiluminescent 
images showing on the z axis the relative intensity of the responce; the luminance of the image is interpreted as height of the 
plot. In the AMI plot (untreated rat) is clearly evident the pro-Cks increase if compared with the ACE-I and Stem plot where, 
on the contrary, the anti-inflammatory Cks are prevalent. Plots are obtained by using Interactive 3D surface plot v2.1 by K. 
Barthel a specific software developed for ImageJ v1.37, a freeware image analysis package developed by W. Rasband. AMI: acute 
myocardial infarction.
Table 1: Pro-inflammatory cytokines in untreated rats: 
comparison with controls
Controls Untreated ANOVA
n = 6 n = 12 p value
IL-1β pg/ml 6.51 ± 6.46 164.20 ± 147.70 0.0020
IL-6 pg/ml 1.76 ± 1.28 954.22 ± 567.23 0.0002
TNFα pg/ml 1.96 ± 1.73 596.45 ± 376.81 0.0001Journal of Translational Medicine 2008, 6:30 http://www.translational-medicine.com/content/6/1/30
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When comparing the effects of a cell therapy approach
(BMMNCs) versus the pharmacological one (ACE-I), we
observed that the reduction in the pro-Cks was similar in
both treatment groups for IL-1β, while for IL-6 and TNFα
it was greater in BMMNC treatment, even if the difference
between the two treatment was not statistical significant.
Furthermore, since in our model the progression to heart
failure is known to be a slow process [16], we didn't find
a significant impairment of LV function in any of the inf-
arcted rats; nonetheless, a favorable effect was detected
over FS that was higher in both treatment groups and over
EF that was higher in ACE-I treated rats. This finding is
coherent with the lower atrial dimensions in treated rats
reflecting a better LV filling pattern, and it could depend
at least in part on the modulation of the pro-Cks cascade,
as shown by the inverse correlation between TNFα and FS.
At this regard, in a recent paper by Boyle et al. [22] the use
of a combined experimental approach including ACE-I, β-
blocker and BM precursors, with known effects on the
pro-Cks cascade following coronary artery ligation in rats,
resulted in the prevention of deterioration of LV function
from day 2 to day 16 post-myocardial infarction.
It should be noticed that our model of myocardial dam-
age, previously described in detail [16,23], differs in some
aspects from the temporary ligation of the artery [24] but
has been proven to facilitate the association of the
injected cells with the infarcted versus non-infarcted areas
and to resemble a typical anterior non transmural myo-
cardial infarction [25], including the inflammatory
response [19].
Conclusion
In the perspective of a future application, the potential
benefit of the use of cell therapy after myocardial infarc-
tion seems to be, at least in part, related to the modulation
of the inflammatory response consisting in lowering the
serum pro-Cks, that are known to contribute to myocar-
dial apoptosis, necrosis, and scar formation [26]. These
actions are associated with a concurrent effect on the anti-
inflammatory cytokines, namely the regulation of IL-4
function, possibly via a direct effect on the lymphocyte T
population. The effects of the cell therapy approach on the
cytokine system associated with the previously demon-
strated contribution to form CD34+ independent vascular
structures [8,27] are probably the main mechanisms of
benefit of cell therapy.
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Table 3: Effects of treatment on LV dimensions and function
-1 days 0 days # 7 days 14 days
UT ACE-I BMMNCs UT ACE-I BMMNCs UT ACE-I BMMNCs UT ACE-I BMMNCs
LAd mm 2.3 ± 0.2 2.2 ± 0.2 2.2 ± 0.3 3.2 ± 0.3 2.7 ± 0.4* 3.1 ± 0.4 3.4 ± 0.2 2.7 ± 0.4** 3.1 ± 0.3 3.5 ± 0.3 2.7 ± 0.4* 2.6 ± 0.6*
LVEDd mm 5.0 ± 0.5 5.1 ± 0.1 5.1 ± 0.2 5.5 ± 0.5 5.2 ± 0.2 5.4 ± 0.3 5.5 ± 0.7 5.3 ± 0.2 5.4 ± 0.2 5.6 ± 0.7 5.4 ± 0.2 5.3 ± 0.3
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LAd = Left Atrial Diameter; LVEDd = Left Ventricular End Diastolic Diameter; E/A = ratio between the velocities of E and A waves of the mitral 
diastolic flow; FS = Fractional Shortening.
# data on day 0 refer to echocardiograms performed 6–24 hours from injury.
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